Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
108.50    -3.00 (-2.65%)
Bid:
108.00
Ask:
112.00
Spread: 4.00 (3.704%)
Market Cap: £66.18m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update, Renewals and New Contract Orders

9 Apr 2026 07:00

RNS Number : 7142Z
Intercede Group PLC
09 April 2026
Β 

9 April 2026

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Β Trading Update, Renewals, Subscription Renewals and New Contract Orders

Β 

Intercede, the leading cybersecurity software company specialising in digital identities, today announces the following trading update for the financial year ending 31 March 2026 (FY26) together with new contract orders and renewals.

Subject to completion of the year-end audit, the Group delivered revenues for FY26 of approximately Β£17.2m (2025: Β£17.7m), representing a decrease of 2.8% year-on-year. On a constant currency basis, Group revenues declined by 0.5%, with subscription revenue increasing by c17.6% and now totalling Β£2.0m (2025: Β£1.7m). As highlighted in the announcement of 17 March 2026, the Group's revenues for FY26 reflect procurement delays, particularly in the United States, and customer purchasing deferrals attributable to heightened geopolitical uncertainty, including the conflict in the Middle East.

Β 

Recurring revenues from support & maintenance, and subscriptions amounted to approximately Β£11.4m, representing c66% of total revenues. This underscores the Group's continued progress in securing new licence wins from both new and existing customers as well as maintaining low customer churn rates.

Β 

As at 31 March 2026, the Group held gross cash balances of Β£20.0m (2025: Β£18.7m). The Group continues to maintain a debt-free balance sheet, providing financial stability and flexibility to support future growth initiatives.

Β 

Further details will be provided within Intercede's final preliminary results which are expected to be published in June 2026.

Β 

The Group is also pleased to announce the following recent renewals and new orders worth c$5.22m in aggregate:

Β 

Β· a large US Federal Government annual subscription renewal for MyID CMS, totalling c$3.49m with a longstanding US client for the period from 1 April 2026 to 31 March 2027. This is the third year of a base year plus four optional incremental year agreement;

Β 

Β· a MyID CMS renewal, subscription and professional services order for a US supervisory banking system, totalling c$0.35m;

Β 

Β· a MyID CMS renewal for a global US defence contractor, totalling c$0.37m;

Β 

Β· a MyID CMS renewal for a global European defence contractor, totalling c$0.23m;

Β 

Β· a MyID CMS renewal for a large North American Telecoms provider, totalling c$0.25m;

Β 

Β· continued professional services order, of more than $0.31m, for an existing POC client in the US federal space, to prepare the groundwork for a future software deployment of MyID CMS;

Β 

Β· a professional services order of c$0.22m with DoS for the continued maintenance of MyID CMS.

Β 

These orders, majority of which are received via our partners, are in line with expectations and reinforce a solid footing as the Group enters the new financial year.

Β 

Klaas van der Leest, CEO, commented:

Β 

"Whilst our revenues for FY26 were impacted by procurement delays and customer purchasing deferrals, what was important to the board was that these opportunities were not lost. Following our update on 17 March, the Group has secured a number of contract renewals and new business wins.

Β 

Furthermore, we are encouraged by customer engagement and the improvement in order intake momentum in the second half of FY26. As we enter the new financial year (FY27), the Group is well placed to build on this momentum, while being mindful of the evolving global macroeconomic environment".

Β 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

Β 

Β 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Marc Milmo/Fergus Sullivan

Corporate Finance

Matt Lewis

ECM

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Β 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

Β 

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI.Β Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and custom development capabilities as well as managing the world's largest password breach database.

Β 

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFZGGDRRKGVZM
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.